Workflow
仙乐健康(300791):3Q25业绩超预期 内生收入增长亮眼

Core Viewpoint - The company reported strong financial performance for the first nine months of 2025, with revenue of 3.291 billion yuan, a year-on-year increase of 8%, and a net profit attributable to shareholders of 260 million yuan, up 8.5% year-on-year, driven by better-than-expected exports in the Americas and business performance in Europe [1] Financial Performance - For 3Q25, the company achieved revenue of 1.25 billion yuan, reflecting a year-on-year growth of 18.1%, and a net profit of 99 million yuan, which is a 16.2% increase year-on-year [1] - The company’s core business showed robust growth, with significant increases in export revenues from China, Europe, and the Americas, estimated at approximately 20%, over 30%, and over 20% year-on-year, respectively [2] - The gross profit margin improved by 1.1 percentage points to 30.8% in 3Q25, mainly due to an enhanced product mix and strong growth in high-margin gummy products and exports to the Americas [2] Future Outlook - The company anticipates steady revenue growth in 4Q25, particularly in the China region, supported by new consumer trends, while the European region is expected to maintain stable growth [3] - The company is focusing on the progress of the BFPC divestiture, which is expected to gradually improve BF's performance [3] Profit Forecast and Valuation - The company is trading at a P/E ratio of 20x for 2025 and 15x for 2026; the profit forecast for 2025 and 2026 has been raised by 1.6% and 1.7% to 360 million yuan and 480 million yuan, respectively [4] - The target price is maintained at 35.3 yuan, corresponding to P/E ratios of 30x and 23x for 2025 and 2026, indicating a potential upside of 54.6% [4]